282 related articles for article (PubMed ID: 20008298)
21. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
22. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
23. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
[TBL] [Abstract][Full Text] [Related]
24. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.
Gill H; Leung AY; Chan CC; Lau JS; Chan C; Yip SF; Liu H; Kho B; Mak V; Lee HK; Lin SY; Lau CK; Kwong YL
Hematology; 2016 Jan; 21(1):10-8. PubMed ID: 26292161
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
Quintás-Cardama A; Tong W; Kantarjian H; Thomas D; Ravandi F; Kornblau S; Manshouri T; Cortes JE; Garcia-Manero G; Verstovsek S
Leukemia; 2008 May; 22(5):965-70. PubMed ID: 18385750
[TBL] [Abstract][Full Text] [Related]
27. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
28. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
[TBL] [Abstract][Full Text] [Related]
29. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
[TBL] [Abstract][Full Text] [Related]
30. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
31. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
Deininger M; Radich J; Burn TC; Huber R; Paranagama D; Verstovsek S
Blood; 2015 Sep; 126(13):1551-4. PubMed ID: 26228487
[TBL] [Abstract][Full Text] [Related]
32. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.
Komrokji RS; Seymour JF; Roberts AW; Wadleigh M; To LB; Scherber R; Turba E; Dorr A; Zhu J; Wang L; Granston T; Campbell MS; Mesa RA
Blood; 2015 Apr; 125(17):2649-55. PubMed ID: 25762180
[TBL] [Abstract][Full Text] [Related]
33. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ
J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243
[TBL] [Abstract][Full Text] [Related]
34. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy.
Silver RT; Vandris K; Wang YL; Adriano F; Jones AV; Christos PJ; Cross NC
Leuk Res; 2011 Feb; 35(2):177-82. PubMed ID: 20650526
[TBL] [Abstract][Full Text] [Related]
35. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
36. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.
Sørensen AL; Mikkelsen SU; Knudsen TA; Bjørn ME; Andersen CL; Bjerrum OW; Brochmann N; Patel DA; Gjerdrum LMR; El Fassi D; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Ellervik C; Pallisgaard N; Thomassen M; Kjær L; Skov V; Hasselbalch HC
Haematologica; 2020 Sep; 105(9):2262-2272. PubMed ID: 33054051
[TBL] [Abstract][Full Text] [Related]
37. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
[TBL] [Abstract][Full Text] [Related]
39. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.
Bellosillo B; Martínez-Avilés L; Gimeno E; Florensa L; Longarón R; Navarro G; Salar A; Espinet B; Solé F; Serrano S; Besses C
Leukemia; 2007 Jun; 21(6):1331-2. PubMed ID: 17361221
[No Abstract] [Full Text] [Related]
40. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
Tefferi A; Lasho TL; Begna KH; Patnaik MM; Zblewski DL; Finke CM; Laborde RR; Wassie E; Schimek L; Hanson CA; Gangat N; Wang X; Pardanani A
N Engl J Med; 2015 Sep; 373(10):908-19. PubMed ID: 26332545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]